T John Martin

List of Publications by Year
in descending order

129 papers	17,156 citations	23500 58 h-index	20900 115 g-index
140 all docs	140 docs citations	140 times ranked	13690 citing authors

#	Article	IF	Citations
1	Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families. Endocrine Reviews, 1999, 20, 345-357.	8.9	2,009
2	Therapeutic Approaches to Bone Diseases. Science, 2000, 289, 1508-1514.	6.0	1,578
3	OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION. Endocrinology, 1988, 123, 2600-2602.	1.4	909
4	Modulation of Osteoclast Differentiation. Endocrine Reviews, 1992, 13, 66-80.	8.9	783
5	Osteoclast-derived activity in the coupling of bone formation to resorption. Trends in Molecular Medicine, 2005, 11, 76-81.	3.5	550
6	Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. BoneKEy Reports, 2014, 3, 481.	2.7	536
7	Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1. Endocrinology, 1999, 140, 4451-4458.	1.4	497
8	The Bone Marrow-Derived Stromal Cell Lines MC3T3-G2/PA6 and ST2 Support Osteoclast-Like Cell Differentiation in Cocultures with Mouse Spleen Cells. Endocrinology, 1989, 125, 1805-1813.	1.4	482
9	Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nature Medicine, 2012, 18, 405-412.	15.2	417
10	Osteotropic Agents Regulate the Expression of Osteoclast Differentiation Factor and Osteoprotegerin in Osteoblastic Stromal Cells. Endocrinology, 1998, 139, 4743-4743.	1.4	404
11	A Combination of Osteoclast Differentiation Factor and Macrophage-Colony Stimulating Factor Is Sufficient for both Human and Mouse Osteoclast Formation in Vitro. Endocrinology, 1998, 139, 4424-4427.	1.4	384
12	Catabolic Effects of Continuous Human PTH (1â€"38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation. Endocrinology, 2001, 142, 4047-4054.	1.4	381
13	Bone metastasis: the importance of the neighbourhood. Nature Reviews Cancer, 2016, 16, 373-386.	12.8	369
14	A novel orthotopic model of breast cancer metastasis to bone. Clinical and Experimental Metastasis, 1999, 17, 163-170.	1.7	367
15	Osteoprotegerin Produced by Osteoblasts Is an Important Regulator in Osteoclast Development and Function*. Endocrinology, 2000, 141, 3478-3484.	1.4	351
16	Transforming Growth Factor Î² Affects Osteoclast Differentiation via Direct and Indirect Actions. Journal of Bone and Mineral Research, 2001, 16, 1787-1794.	3.1	245
17	Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. Journal of Clinical Investigation, 2010, 120, 582-592.	3.9	245
18	Model structure and control of bone remodeling: A theoretical study. Bone, 2008, 43, 249-263.	1.4	237

#	Article	IF	Citations
19	EphrinB2 Regulation by PTH and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts. Journal of Bone and Mineral Research, 2008, 23, 1170-1181.	3.1	191
20	Importin Î² Recognizes Parathyroid Hormone-related Protein with High Affinity and Mediates Its Nuclear Import in the Absence of Importin Î±. Journal of Biological Chemistry, 1999, 274, 7391-7398.	1.6	185
21	Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. Journal of Clinical Investigation, 2004, 113, 379-389.	3.9	175
22	Induction of Calcitonin Receptors by lÎ±, 25- Dihydroxyvitamin D₃in Osteoclast-Like Multinucleated Cells Formed from Mouse Bone Marrow Cells*. Endocrinology, 1988, 123, 1504-1510.	1.4	170
23	Orally Bioavailable GSK-3Î±/Î² Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo. Journal of Bone and Mineral Research, 2006, 21, 910-920.	3.1	164
24	Advances in the biology of bone metastasis: How the skeleton affects tumor behavior. Bone, 2011, 48, 6-15.	1.4	164
25	Cardiotrophin-1 Is an Osteoclast-Derived Stimulus of Bone Formation Required for Normal Bone Remodeling. Journal of Bone and Mineral Research, 2008, 23, 2025-2032.	3.1	163
26	A Carboxyl-Terminal Peptide from the Parathyroid Hormone-Related Protein Inhibits Bone Resorption by Osteoclasts*. Endocrinology, 1991, 129, 1762-1768.	1.4	159
27	RANKL/OPG; Critical role in bone physiology. Reviews in Endocrine and Metabolic Disorders, 2015, 16, 131-139.	2.6	158
28	Osteoclasts Provide Coupling Signals to Osteoblast Lineage Cells Through Multiple Mechanisms. Annual Review of Physiology, 2020, 82, 507-529.	5.6	154
29	Bone remodelling: its local regulation and the emergence of bone fragility. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 701-722.	2.2	149
30	Twenty-five years of PTHrP progress: From cancer hormone to multifunctional cytokine. Journal of Bone and Mineral Research, 2012, 27, 1231-1239.	3.1	145
31	Molecular Mechanisms in Coupling of Bone Formation to Resorption. Critical Reviews in Eukaryotic Gene Expression, 2009, 19, 73-88.	0.4	142
32	Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface?. Frontiers in Endocrinology, 2015, 6, 41.	1.5	140
33	Interleukin-11 Receptor Signaling Is Required for Normal Bone Remodeling. Journal of Bone and Mineral Research, 2005, 20, 1093-1102.	3.1	138
34	Parathyroid Hormoneâ€“Related Protein Localization in Breast Cancers Predict Improved Prognosis. Cancer Research, 2006, 66, 2250-2256.	0.4	124
35	Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases. Physiological Reviews, 2016, 96, 831-871.	13.1	123
36	Osteoclast-Derived Coupling Factors in Bone Remodeling. Calcified Tissue International, 2014, 94, 88-97.	1.5	120

#	Article	IF	Citations
37	Parathyroid Hormone-Related Protein Production by Breast Cancers, Improved Survival, and Reduced Bone Metastases. Journal of the National Cancer Institute, 2001, 93, 234-237.	3.0	110
38	Fetal parathyroids are not required to maintain placental calcium transport. Journal of Clinical Investigation, 2001, 107, 1007-1015.	3.9	110
39	Osteoblast-derived PTHrP is a physiological regulator of bone formation. Journal of Clinical Investigation, 2005, 115, 2322-2324.	3.9	110
40	Nuclear Transport of Parathyroid Hormone (PTH)-Related Protein Is Dependent on Microtubules. Molecular Endocrinology, 2002, 16, 390-401.	3.7	104
41	Parathyroid hormoneâ€related protein: a possible endocrine function in lactation. Clinical Endocrinology, 1992, 37, 405-410.	1.2	102
42	A Combination of Osteoclast Differentiation Factor and Macrophage-Colony Stimulating Factor Is Sufficient for both Human and Mouse Osteoclast Formation in Vitro. , 0, .		101
43	Expression of parathyroid hormone-related protein in cells of osteoblast lineage. , 1996, 166, 94-104.		100
44	Parathyroid hormone-related protein and hypercalcemia. Cancer, 1997, 80, 1564-1571.	2.0	96
45	EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. Journal of Bone and Mineral Research, 2013, 28, 912-925.	3.1	93
46	The Primary Function of gp130 Signaling in Osteoblasts Is To Maintain Bone Formation and Strength, Rather Than Promote Osteoclast Formation. Journal of Bone and Mineral Research, 2014, 29, 1492-1505.	3.1	90
47	Cloning of an osteoblastic cell line involved in the formation of osteoclast-like cells. Journal of Cellular Physiology, 1990, 145, 587-595.	2.0	86
48	Phosphorylation at the Cyclin-dependent Kinases Site (Thr85) of Parathyroid Hormone-related Protein Negatively Regulates Its Nuclear Localization. Journal of Biological Chemistry, 1999, 274, 18559-18566.	1.6	86
49	Inhibitory effects of parathyroid hormone on growth of osteogenic sarcoma cells. Calcified Tissue International, 1985, 37, 519-525.	1.5	84
50	Regulation of alkaline phosphatase expression in a neonatal rat clonal calvarial cell strain by retinoic acid. Journal of Bone and Mineral Research, 1988, 3, 53-61.	3.1	83
51	Structural requirements for the action of parathyroid hormone-related protein (PTHrP) on bone resorption by isolated osteoclasts. Journal of Bone and Mineral Research, 1991, 6, 85-93.	3.1	77
52	Differentiation potential of a mouse bone marrow stromal cell line. Journal of Cellular Biochemistry, 2003, 90, 158-169.	1.2	75
53	Zinc Finger Protein 467 Is a Novel Regulator of Osteoblast and Adipocyte Commitment. Journal of Biological Chemistry, 2011, 286, 4186-4198.	1.6	71
54	EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis. FASEB Journal, 2014, 28, 4482-4496.	0.2	70

#	Article	IF	Citations
55	Matrix Rigidity Induces Osteolytic Gene Expression of Metastatic Breast Cancer Cells. PLoS ONE, 2010, 5, e15451.	1.1	70
56	Activity Ratio Measurements Reflect Intracellular Activation of Adenosine 3â€²,5â€²-Monophosphate-Dependent Protein Kinase in Osteoblasts*. Endocrinology, 1982, 111, 178-183.	1.4	65
57	Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. Bone, 2013, 55, 166-178.	1.4	65
58	Bone Biology and Anabolic Therapies for Bone: Current Status and Future Prospects. Journal of Bone Metabolism, 2014, 21, 8.	0.5	63
59	Ciliary Neurotrophic Factor Inhibits Bone Formation and Plays a Sex-Specific Role in Bone Growth and Remodeling. Calcified Tissue International, 2010, 86, 261-270.	1.5	62
60	Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells. Journal of Cellular Physiology, 1991, 149, 34-43.	2.0	59
61	Parathyroid hormone-related protein and hypercalcemia. Cancer, 1997, 80, 1564-71.	2.0	57
62	T-Cells Mediate an Inhibitory Effect of Interleukin-4 on Osteoclastogenesis. Journal of Bone and Mineral Research, 2003, 18, 984-993.	3.1	56
63	Changes in Osteoblast, Chondrocyte, and Adipocyte Lineages Mediate the Bone Anabolic Actions of PTH and Small Molecule GSK-3 Inhibitor. Journal of Cellular Biochemistry, 2007, 102, 1504-1518.	1.2	56
64	The Chemokine Cxcl1 Is a Novel Target Gene of Parathyroid Hormone (PTH)/PTH-Related Protein in Committed Osteoblasts. Endocrinology, 2009, 150, 2244-2253.	1.4	54
65	Historically significant events in the discovery of RANK/RANKL/OPG. World Journal of Orthopedics, 2013, 4, 186.	0.8	54
66	Autocrine and Paracrine Regulation of the Murine Skeleton by Osteocyte-Derived Parathyroid Hormone-Related Protein. Journal of Bone and Mineral Research, 2018, 33, 137-153.	3.1	54
67	Myokines (muscle-derived cytokines and chemokines) including ciliary neurotrophic factor (CNTF) inhibit osteoblast differentiation. Bone, 2014, 64, 47-56.	1.4	53
68	The role of vitamin A and retinoic acid receptor signaling in post-natal maintenance of bone. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 135-146.	1.2	53
69	Mechanisms Involved in Skeletal Anabolic Therapies. Annals of the New York Academy of Sciences, 2006, 1068, 458-470.	1.8	50
70	Parathyroid hormone-related protein relaxes rat gastric smooth muscle and shows cross-desensitization with parathyroid hormone. Journal of Bone and Mineral Research, 1989, 4, 433-439.	3.1	49
71	Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo. Journal of Bone and Mineral Research, 2012, 27, 902-912.	3.1	49
72	Nuclear and nucleolar localization of parathyroid hormoneâ€related protein. Immunology and Cell Biology, 2000, 78, 395-402.	1.0	48

#	Article	IF	Citations
73	Increased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone. Nature Communications, 2019, 10, 3436.	5.8	48
74	Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone. Bone, 2015, 81, 343-351.	1.4	47
75	New mechanisms and targets in the treatment of bone fragility. Clinical Science, 2007, 112, 77-91.	1.8	46
76	Isolation and gene expression of haematopoietic-cell-free preparations of highly purified murine osteocytes. Bone, 2015, 72, 34-42.	1.4	42
77	Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R. Endocrine Reviews, 2021, 42, 383-406.	8.9	41
78	Does bone resorption inhibition affect the anabolic response to parathyroid hormone?. Trends in Endocrinology and Metabolism, 2004, 15, 49-50.	3.1	40
79	Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporosis International, 2008, 19, 1125-1138.	1.3	39
80	Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. Cytokine, 2014, 68, 101-109.	1.4	38
81	Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance. ELife, 2016, 5, .	2.8	38
82	Plasminogen activator regulation in osteoblasts: Parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA. Journal of Cellular Physiology, 1992, 152, 346-355.	2.0	37
83	Multiple actions of parathyroid hormoneâ€related protein in breast cancer bone metastasis. British Journal of Pharmacology, 2021, 178, 1923-1935.	2.7	36
84	The DNA Helicase Recql4 Is Required for Normal Osteoblast Expansion and Osteosarcoma Formation. PLoS Genetics, 2015, 11, e1005160.	1.5	34
85	Osteoclast Inhibitory Lectin, an Immune Cell Product That Is Required for Normal Bone Physiology in Vivo. Journal of Biological Chemistry, 2008, 283, 30850-30860.	1.6	28
86	Abaloparatide Is an Anabolic, but Does It Spare Resorption?. Journal of Bone and Mineral Research, 2017, 32, 11-16.	3.1	28
87	Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and is not silenced by DNA methylation in osteosarcoma. Bone, 2015, 73, 223-232.	1.4	27
88	gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation. Journal of Endocrinology, 2014, 223, 181-190.	1.2	26
89	New therapeutics for osteoporosis. Current Opinion in Pharmacology, 2014, 16, 58-63.	1.7	26
90	RARÎ³ is a negative regulator of osteoclastogenesis. Journal of Steroid Biochemistry and Molecular Biology, 2015, 150, 46-53.	1.2	25

#	Article	IF	Citations
91	Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation. Bone, 2016, 93, 146-154.	1.4	25
92	Chondrocytic EphrinB2 promotes cartilage destruction by osteoclasts in endochondral ossification. Development (Cambridge), 2016, 143, 648-57.	1.2	25
93	Parathyroid Hormone-Related Protein Negatively Regulates Tumor Cell Dormancy Genes in a PTHR1/Cyclic AMP-Independent Manner. Frontiers in Endocrinology, 2018, 9, 241.	1.5	25
94	Arg21 is the Preferred Kexin Cleavage Site in Parathyroid-Hormone-Related Protein. FEBS Journal, 1995, 229, 91-98.	0.2	22
95	Cortical bone maturation in mice requires SOCS3 suppression of gp130/STAT3 signalling in osteocytes. ELife, 2020, 9, .	2.8	21
96	Decline in calcitonin receptor expression in osteocytes with age. Journal of Endocrinology, 2014, 221, 181-191.	1.2	20
97	A skeleton key to metabolism. Nature Medicine, 2007, 13, 1021-1023.	15.2	19
98	Calcitonin Physiology, Saved by a Lysophospholipid. Journal of Bone and Mineral Research, 2015, 30, 212-215.	3.1	19
99	Manipulating the environment of cancer cells in bone: a novel therapeutic approach. Journal of Clinical Investigation, 2002, 110, 1399-1401.	3.9	15
100	Expression of Rat Homeobox Gene, rHOX, in Developing and Adult Tissues in Mice and Regulation of Its mRNA Expression in Osteoblasts by Bone Morphogenetic Protein 2 and Parathyroid Hormone-Related Protein. Molecular Endocrinology, 1998, 12, 1721-1732.	3.7	14
101	HUMORAL HYPERCALCEMIA OF MALIGNANCY: INVOLVEMENT OF A NOVEL HORMONE. Australian and New Zealand Journal of Medicine, 1988, 18, 287-295.	0.5	12
102	Coupling Factors: How Many Candidates Can There Be?. Journal of Bone and Mineral Research, 2014, 29, 1519-1521.	3.1	12
103	Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53. Cell Death and Disease, 2018, 9, 844.	2.7	12
104	PTHrP, its receptor, and protein kinase A activation in osteosarcoma. Molecular and Cellular Oncology, 2014, 1, e965624.	0.3	11
105	Brief exposure to full length parathyroid hormone-related protein (PTHrP) causes persistent generation of cyclic AMP through an endocytosis-dependent mechanism. Biochemical Pharmacology, 2019, 169, 113627.	2.0	9
106	Coupling: The Influences of Immune and Bone Cells. , 2016, , 169-185.		8
107	PTH1R Actions on Bone Using the cAMP/Protein Kinase A Pathway. Frontiers in Endocrinology, 2021, 12, 833221.	1.5	8
108	Protein nutrition as therapy for a genetic disorder of bone?. Cell Metabolism, 2006, 4, 419-420.	7.2	6

#	Article	IF	Citations
109	Bone Geometry Is Altered by Follistatinâ€Induced Muscle Growth in Young Adult Male Mice. JBMR Plus, 2021, 5, e10477.	1.3	6
110	The osteoblast lineage. , 2020, , 89-110.		5
111	Coupling of bone formation and resorption. , 2020, , 219-243.		4
112	<i>Dmp1Cre-</i>directed knockdown of parathyroid hormoneâ€"related protein (PTHrP) in murine decidua is associated with a life-long increase in bone mass, width, and strength in male progeny. Journal of Bone and Mineral Research, 2020, 36, 1999-2016.	3.1	4
113	New functions for old hormones: Bone as an endocrine organ. Molecular and Cellular Endocrinology, 2009, 310, 1-2.	1.6	3
114	Interactions Among Osteoblasts, Osteoclasts, and Other Cells in Bone. , 2011, , 227-267.		3
115	Basic Principles of Bone Cell Biology. , 2013, , 5-26.		3
116	Paracrine parathyroid hormoneâ€"related protein in bone: physiology and pharmacology. , 2020, , 595-621.		3
117	Intercellular Communication during Bone Remodeling. , 2008, , 547-560.		2
118	Aspects of intercellular communication in bone and implications in therapy. Bone, 2021, 153, 116148.	1.4	2
119	New agents for the treatment of osteoporosis. BoneKEy Osteovision, 2007, 4, 287-298.	0.6	2
120	Foreword: Skeletal Complications of Cancer. Bone, 2011, 48, 5.	1.4	1
121	Historical Perspective and Evolutionary Origins of Parathyroid Hormone-Related Protein. Clinical Reviews in Bone and Mineral Metabolism, 2014, 12, 104-118.	1.3	1
122	Comment on: Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Non-Canonical cAMP/PKA Pathways. Journal of Bone and Mineral Research, 2015, 30, 2133-2134.	3.1	1
123	Dual posttranscriptional targets of retinoic acid-induced gene expression. Journal of Cellular Biochemistry, 1999, 72, 411-422.	1.2	0
124	David Valor Cohn (1926â€"2006). Bone, 2006, 38, 611-612.	1.4	0
125	Human embryonic stem cells leap the barrier. Medical Journal of Australia, 2007, 187, 477-478.	0.8	0
126	Advances in the molecular pharmacology and therapeutics of bone disease and international symposium on paget's disease. IBMS BoneKEy, 2009, 6, 439-445.	0.1	0

#	Article	IF	Citations
127	Reflections on Development of Concepts of Intercellular Communication in Bone. , 2013, , 51-69.		0
128	Integrating Endocrine and Paracrine Influences on Bone; Lessons From Parathyroid Hormone and Parathyroid Hormone-Related Protein. , 2018, , 283-299.		0
129	Remembering Dr John D Termine. Journal of Bone and Mineral Research, 2020, 36, 1647-1648.	3.1	0